6533b839fe1ef96bd12a634b

RESEARCH PRODUCT

LEOPARD-II: A randomized phase II study of radiochemotherapy (RCT) with 5FU and cisplatin plus/minus cetuximab (Cet) in unresectable locally advanced esophageal cancer (LAEC).

Dirk RadesRenato ReyesCordula PetersenNils HomannMarkus MoehlerJuergen DebusAnne L KranichKarsten RidwelskiClaus Belka

subject

CisplatinOncologyCancer ResearchPoor prognosismedicine.medical_specialtyCetuximabbusiness.industryLocally advancedPhases of clinical researchEsophageal cancermedicine.diseaselaw.inventionOncologyRandomized controlled triallawInternal medicinemedicinebusinessmedicine.drug

description

4081 Background: Patients (pts) with LAEC have a poor prognosis; new therapies are required. A study showed the addition of Cet to RCT to be safe and effective for resectable EC [Ruhstaller et al, ...

https://doi.org/10.1200/jco.2014.32.15_suppl.4081